A new way of inhibiting tumor necrosis factor (TNF) for treating rheumatoid arthritis showed strong results in a phase II/III clinical trial, researchers said.
About 75% to 80% of patients receiving an investigational agent called ozoralizumab achieved 20% reductions in symptoms by
Read Article
Analysis of two large clinical trial datasets shows that placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis are better when the patient continued background methotrexate (MTX).
RA patients with an insufficient MTX can either continue
Read Article
The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,
Read Article
Hydroxychloroquine (HCQ) appeared less safe from a cardiovascular standpoint than methotrexate in older patients with rheumatoid arthritis (RA), analysis of Medicare data indicated.
Among RA patients 65 and older with a history of heart failure, major cardiovascular events occurred
Read Article
The US Preventive Services Task Force (USPSTF) has updated its recommendations regarding the efficacy of supplements or multivitamins for reducing the risk of cardiovascular disease, cancer, and mortality in the general adult population.
The USPSTF concluded there is insufficient
Read Article
Pooled data from two large ixekizumab (IXE) trials show that male patients had greater clinical responses than did female patients with psoriatic arthritis are largely unexplored. Reasons for this differential treatment responses to an interleukin-17A inhibitor (IXE) between male and female
Read Article
A cohort study of rheumatoid arthritis (RA) patients evaluated immunogenicity of COVID vaccination with and without holding methotrexate (MTX) for and 2-weeks and showed better immunogenicity, but more RA flares with the second MTX withdrawal.
Read Article
A pooled analyses of data from eight, phase 2 and 3 randomized clinical trials shows bimekizumab, a dual IL-17A/F inhibitor, to be effective in plaque psoriasis and was well tolerated aside from an increased incidence of mild to moderate oral candidiasis.
The cohort included 1789
Read Article
Clear differences were apparent among the three major types of targeted medications for rheumatoid arthritis (RA) in a large European registry study.
For one, patients using inhibitors of the Janus-associated kinase (JAK) pathway were more likely to stop them because of adverse
Read Article
An Annals of Internal Medicine review has shown that clinical trials and cohort studies of cannabinoids use for chronic pain may be associated with short-term improvements in chronic pain but come with an increased risk for dizziness and sedation. Studies of long-term outcomes and
Read Article
The British Society of Rheumatology has published their updated 2022 recommendations for the use of biologics and targeted synthetic treatments in patients iwth psoriatic arthritis. These guidelines follow initial treatment with a single conventional systemic disease-modifying anti-rheumatic
Read Article
Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.
Read Article
Mortality rates among patients with giant cell arteritis (GCA) in Canada's Ontario province rose by 15% from 2000 to 2018, a new study found, even as the general population saw declines in overall mortality.
In 2000, mortality in GCA patients stood at 50.0 per 1,000 patients. By 2018
Read Article
Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). Rheumatic complaints may be less frequent than other irAEs associated with ICI in cancer patients.
Read Article
A one year, X-ray outcome trial has shown that the initial use of prednisone (high or low dose) in newly treated active early rheumatoid arthritis (RA) did not improve radiographic outcomes.
Early use of glucocorticoids are often used as "bridge therapy" to afford clinical relief
Read Article
This week's Tuesday Night Rheumatology, hosted by Dr. Jack Cush, featured highlights from the 2022 RheumNow Live Rheumatoid Arthritis - Best Management Pod, followed by a lively audience Q & A. Lectures featured:
- Drug Cycling Vs Switching in RA - Janet Pope, MD, MPH,
Read Article
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?
May 2022 EMA meeting the CHMP recommended new indications for
JAMA reports that despite NIH recommendations (that corticosteroids only be used in hospitalized COVID-19 patients), nonhospitalized COVID infected patients were oftent prescribed systemic corticosteroids.
The use and efficacy of corticosteroids in COVID, including the
Read Article
Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. Until recently there were few studies to support it's benefit in rheumatoid arthritis (RA) or psoriatic arthritis (PsA), but now EULAR has
Read Article
SGLT2 inhibitors are all the buzz in the renal world with reports of a renal protective and mortality lowering effects. Maybe these agents should be considered and studied in lupus nephritis and ANCA- associated vasculitis.
Sodium–glucose cotransporter 2 (SGLT2) inhibitors haven been
Read Article
Both old and newer pharmacological treatments for fibromyalgia are often promoted; but a recent systematic review and network meta-analysis showed that duloxetine had higher efficacy in pain and depression, while amitriptyline had higher efficacy in treating sleep, fatigue, and quality of life
Read Article
Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.
Read Article
A novel study from the Journal of Experimental Medicine suggests that a reflex neural signaling at sites of inflammation may lead to spread to other inflammatory sites via and ATP-mediated neural crosstalk. Such findings may be important in disorders like rheumatoid arthritis (RA)
Read Article
This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.
- Microbiome in Spondyloathritis - Jose Scher, MD
- Axial Psoriatic Arthritis - Philip Mease, MD
- Juvenile Spondyloathritis - Pamela Weiss, MD
Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.
This population-based study examined prevalent RA as of January 2015 and sought to
Read Article
